Evaluation of The Efficacy And Safety of Intra-Articular Etanercept in Patients With Refractory Knee Joint Synovitis
Status:
Completed
Trial end date:
2007-12-01
Target enrollment:
Participant gender:
Summary
To assess the therapeutic efficacy, of the clinical response of intraarticular (IA)
etanercept (E) 12.5 mg or placebo (P: NaCl) injections into single knee arthritic joint of
patients with refractory knee joint synovitis (KJS), administered once every two week, for
eight weeks, with cross over after 2 weeks, in two groups of randomly assigned patients, for
whom traditional systemic disease-modifying antirheumatic drugs (DMARDs) is insufficient or
inappropriate. The primary outcome measure is the Thompson articular index of KJS disease
activity.
Phase:
Phase 2
Details
Lead Sponsor:
University of Padova
Collaborators:
Azienda Ospedaliera di Padova Wyeth is now a wholly owned subsidiary of Pfizer